Genomic landscape and chronological reconstruction of driver events in multiple myeloma-Reference-Cited by-同舟云学术

Genomic landscape and chronological reconstruction of driver events in multiple myeloma

Published:2019-08-23 Issue:1 Volume:10 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Maura Francesco,Bolli Niccoló,Angelopoulos Nicos,Dawson Kevin J.,Leongamornlert Daniel,Martincorena Inigo,Mitchell Thomas J.^ORCID,Fullam Anthony,Gonzalez Santiago^ORCID,Szalat Raphael,Abascal Federico^ORCID,Rodriguez-Martin Bernardo,Samur Mehmet Kemal,Glodzik Dominik^ORCID,Roncador Marco,Fulciniti Mariateresa,Tai Yu Tzu,Minvielle Stephane,Magrangeas Florence,Moreau Philippe,Corradini Paolo,Anderson Kenneth C.,Tubio Jose M. C.,Wedge David C.,Gerstung Moritz^ORCID,Avet-Loiseau Hervé,Munshi Nikhil,Campbell Peter J.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-019-11680-1.pdf

Reference53 articles.

1. Corre, J., Munshi, N. & Avet-Loiseau, H. Genetics of multiple myeloma: another heterogeneity level? Blood 125, 1870–1876 (2015).

2. Manier, S. et al. Genomic complexity of multiple myeloma and its clinical implications. Nat. Rev. Clin. Oncol. 14, 100–113 (2017).

3. Morgan, G. J., Walker, B. A. & Davies, F. E. The genetic architecture of multiple myeloma. Nat. Rev. Cancer 12, 335–348 (2012).

4. Walker, B. A. et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat. Commun. 6, 6997 (2015).

5. Bolli, N. et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun. 5, 2997 (2014).

Cited by 202 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma;2024-09-04

2. Toll-like receptor-1 (TLR-1) activation reduces immunoglobulin free light chain production by multiple myeloma cells in the context of bone marrow stromal cells and fibronectin;2024-09-03

3. Description of Feelings, Perception, and Experience Before and After Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in Europe;Patient Preference and Adherence;2024-09

4. The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma;Blood;2024-08-15

5. Role and timing of chromosome deletions in multiple myeloma;Blood;2024-08-15